Board of Directors



Mr. Lyons has been a member of the board of directors of Retrophin, Inc. since 2014 and assumed the role of chairman in May of 2016. Previously, Mr. Lyons was the founding president and chief executive officer of Neurocrine Biosciences from 1993 to 2008 and remains as a member of the board of directors. Prior to his work at Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, Inc., including vice president of business development and vice president of sales. Mr. Lyons currently serves as chairman of the board of directors for Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and metabolic diseases. He also serves as a director for Vical Incorporated, a biotechnology company focused on the prevention and treatment of serious or life-threatening diseases. Mr. Lyons was previously a director of PDL BioPharma, Inc., NeurogesX, Inc., and Facet Biotech Corporation. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an MBA from Northwestern University's J.L. Kellogg Graduate School of Management.

STEPHEN ASELAGE                                                                      

Mr. Aselage has been a member of the board of directors of Retrophin, Inc. since 2012. During his tenure as CEO of Retrophin from 2014 to January 2019, Mr. Aselage drew upon more than 30 years of biopharmaceutical experience to lead the transformation of the company. Following his appointment, Mr. Aselage solidified the company's leadership, led an operational review of pipeline and commercial assets, and built a growth strategy around investigational and commercial therapies to bring long-term value to patients and shareholders. Prior to his appointment , Mr. Aselage was executive vice president and chief business officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, Mr. Aselage built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. Mr. Aselage worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat, and earlier in his career, held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi) and Bristol Laboratories. Mr. Aselage is also a member of the board of directors for Acer Therapeutics and BioCryst. Mr. Aselage received his B.S. in biology from the University of Notre Dame, currently serves on the advisory council for the department of science at Notre Dame.


Dr. Baynes has been a member of the board of directors of Retrophin, Inc. since 2016. Currently, Dr. Baynes is senior vice president of global clinical development at Merck Research Laboratories. Prior to his role at Merck, Dr. Baynes was senior vice president of oncology, inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., which was preceded by his service at Amgen, Inc. as vice president of global clinical development and therapeutic area head for hematology/oncology. Before joining Amgen, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. Dr. Baynes received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa, and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital.

Suzanne L. Bruhn, Ph.D.

Dr. Bruhn has been a member of the board of directors of Retrophin, Inc. since 2020. She brings to the Retrophin board more than 20 years of biopharmaceutical experience and a proven track record of success in the development and commercialization of therapies for the treatment of serious diseases with significant unmet needs. Dr. Bruhn serves as the president and chief executive officer of biotechnology company Tiaki Therapeutics Inc., where she is responsible for the vision and overall corporate and capital strategy of the company as it develops innovative therapeutics for patients with neurodegenerative diseases. Prior to her role at Tiaki, Dr. Bruhn served as the president and chief executive officer of Proclara Biosciences where she led the company’s strategy to develop novel treatments for neurodegenerative and peripheral protein misfolding diseases. Before joining Proclara, Dr. Bruhn served as president and chief executive officer of Promedior, Inc., where she focused the company’s strategy on clinical stage development for rare diseases. Earlier in her career, Dr. Bruhn spent 13 years at Shire Human Genetic Therapies, where she held a series of positions of increasing responsibility, including leading global regulatory affairs, strategic planning and program management. Dr. Bruhn currently serves as an independent director on the boards of clinical stage biotechnology companies Aeglea BioTherapeutics and Pliant Therapeutics. She holds a bachelor’s degree in chemistry from Iowa State University, a Ph.D. in chemistry from the Massachusetts Institute of Technology, and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School.


Mr. Coughlin has been a member of the board of directors of Retrophin, Inc. since 2015. Mr. Coughlin is the former CFO of Neurocrine Biosciences having served there from 2002 to 2018. Mr. Coughlin has developed expertise in corporate accounting, finance, and operations management of companies ranging in size from start-ups through Fortune 500. Prior to Neurocrine, he served as vice president of financial services at CHI, a nationwide integrated healthcare delivery system. From 1989 to 1999, Mr. Coughlin served as a senior manager in the health sciences practice of Ernst & Young, and its predecessors. Mr. Coughlin currently serves on the board of directors of aTyr Pharma, Inc., a biopharmacuetical company focused on immunotherapies for cancer and immune disorders, and of Fate Therapeutics, a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat severe, life-threatening diseases. Mr. Coughlin holds a bachelor's in accounting from Temple University and a master's in international business from San Diego State University.

Eric Dube, Ph.D.

Dr. Dube has been the president and chief executive officer of Retrophin, Inc. and member of the company's board of directors since January 2019. He is a results-driven leader with a record of delivering innovative therapies to address significant unmet patient needs. Dr. Dube oversees a global team of 225+ employees who are dedicated to identifying, developing and delivering life-changing therapies to people living with rare disease, as well as the advancement of the company’s promising pipeline featuring an innovative product candidate with first-in-class potential. With leadership experience across the United States, Europe and Japan, Dr. Dube draws upon significant expertise in managing commercial, operations, market access, medical, and business development functions. He leads with a commitment to patients, integrating their perspective into all aspects of the company's operations. Prior to joining Retrophin, Dr. Dube was president and head of North America at ViiV Healthcare, where he led the commercialization of pipeline assets and oversaw the governance of all pricing, strategy, policy, and investment decisions for the company's North America business. Before joining ViiV, for more than 18 years he worked in roles of increasing leadership at GlaxoSmithKline plc, spanning critical areas, including sales, marketing, market access, medical affairs, compliance, supply chain, and alliance management. During Dr. Dube's tenure at GSK, he also led the US oncology and global respiratory businesses. Dr. Dube currently serves on the board of trustees for AIDS United and the board of directors for the Biotechnology Innovation Organization (BIO). He has previously been named a Fortune magazine "40 Under 40: Ones to Watch" and one of the "Emerging Pharma Leaders" by Pharmaceutical Executive. Dr. Dube has also been named by the Financial Times as one of the "OUTstanding 100 LGBT+ Executives." Dr. Dube graduated from Santa Clara University with a B.S. in biopsychology and earned an M.A. and Ph.D. in Psychology from Cornell University, where his studies focused on how culture, gender and ethnicity influenced resilience in the LGBTQ community.


Mr. Meckler has been a member of the board of directors of Retrophin, Inc. since 2014. He brings extensive biopharmaceutical industry experience to Retrophin and is currently the chief executive officer at Intec Pharma, Ltd. – a clinical stage biopharmaceutical company focused on developing a proprietary drug delivery solution for key unmet needs. Previously, he served as CEO and a director of Cocrystal Pharma, Inc. a pharmaceutical company focused on the discovery of novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Earlier in his career, Mr. Meckler was managing director of the Andra Group, a life sciences consulting firm and acted as a director and interim CEO of Cypress Bioscience Inc. after its acquisition by Royalty Pharma. He has also served as a director of QLT, Inc., ClearFarma USA, Kyalin Bioscience and Alveolus Inc. Mr. Meckler held a series of positions at Pfizer Inc. in manufacturing systems, market research, business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures. Mr. Meckler is the past president and continues to serve on the board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. Mr. Meckler holds a B.S. in industrial management and M.S. in industrial administration from Carnegie Mellon University's Tepper School of Business. In addition, Mr. Meckler received a J.D. from Fordham University School of Law.

john A. orwin

Mr. Orwin has been a member of the board of directors of Retrophin, Inc. since 2017. Mr. Orwin has cultivated more than 25 years of biopharmaceutical experience during tenures at some of the industry's leading companies. Currently, Mr. Orwin serves as the president and chief executive officer (CEO) of Atreca, Inc., a biopharmaceutical company focused on developing novel therapeutics based on a deep understanding of the human immune response. Prior to Atreca, Mr. Orwin also served as CEO of Relypsa, and as a director and CEO of Affymax, which was preceded by a tenure as the company's chief operating officer. In building successful businesses and commercializing a range of blockbuster products, Mr. Orwin has held leadership roles in marketing, sales, and operations for Genentech, Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer, and Schering-Plough Corporation. Mr. Orwin is currently a member of the board of directors of Array BioPharma Inc. and Seattle Genetics, Inc. Mr. Orwin holds a master's degree in business administration from New York University and a bachelor's degree from Rutgers, The State University of New Jersey.

Sandra E. Poole

Ms. Poole has been a member of the board of directors of Retrophin, Inc. since 2019. She brings to Retrophin more than 25 years of biotechnology industry experience in manufacturing strategy, including chemistry, manufacturing and controls (CMC), technical operations, and product development from research through commercialization. Ms. Poole serves as the chief operating officer of Mythic Therapeutics, an early-stage biotechnology company focused on cancer therapies. Before that, she served as the chief operating officer of LogicBio Therapeutics, Inc., a genome editing company, where she was responsible for leading the company’s internal operations, including all technical functions, quality and regulatory, and supported a successful initial public offering. Prior to LogicBio, Ms. Poole held executive roles of increasing responsibility at ImmunoGen, Inc., a company developing antibody-drug conjugates (ADCs) to treat cancer. While at ImmunoGen, she built technical development and CMC capabilities and built a network of contract manufacturing organizations to manufacture ADCs. Before joining ImmunoGen, Ms. Poole spent more than 15 years in global manufacturing and development leadership positions at Genzyme (now Sanofi Genzyme). Ms. Poole currently serves on the board of directors of ViaCyte, a company focused on regenerative medicine technology to address beta cell loss in type 1 diabetes. Ms. Poole holds an M.A.Sc. and a B.A.Sc. in chemical engineering from the University of Waterloo (Canada).

Ron Squarer

Mr. Squarer has been a member of the board of directors of Retrophin, Inc. since 2017. Mr. Squarer has extensive commercial, development and executive leadership expertise from a career that spans more than two decades in the biopharmaceutical industry. Mr. Squarer served as chief executive officer and a member of the board of directors of Array BioPharma, Inc. from 2012 until its acquisition by Pfizer in 2019. Prior to this, Mr. Squarer held positions of increasing responsibility with Hospira Inc., a global pharmaceutical and medical device company, most recently serving as senior vice president, chief commercial officer, where he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as senior vice president, global corporate and business development when Mayne was sold to Hospira in 2007. Prior to Mayne Pharma, Mr. Squarer held senior management roles at both Pfizer, Inc., and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the US and Europe. He currently serves as a member of the board of directors for Deciphera Pharmaceuticals and as the chairman of the board at ADC Therapeutics. Mr. Squarer holds an MBA from the Kellogg School of Management, Northwestern University and a bachelor's degree in biochemistry from the University of California, Berkeley.